Reema Rajbhandari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Reema Rajbhandari has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Ragesh Karn
Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal
7 shared publications - Rajeev Ojha
Department of Neurology Tribhuvan University Institute of Medicine Teaching Hospital Kathmandu Nepal
7 shared publications - Bikram Prasad Gajurel
Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
6 shared publications - Aashish Shrestha
Department of Neurology, Tribhuvan University Teaching Hospital
4 shared publications - Niraj Gautam
Department of Neurology, Institute of Medicine, Kathmandu, Nepal
4 shared publications - Subarna Giri
Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
3 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 22 (2) , 1-2
Bridging Minds and Vision: The Need for Neurology and Ophthalmology Synergy in Multiple Sclerosis
Multiple sclerosis (MS) continues to challenge clinicians and researchers alike with its non-specific and heterogeneous presentation and unpredictable course. Among its earliest and most presenting features is visual dysfunction—commonly optic neuritis—which not only reflects localized optic nerve inflammation but also serves as a harbinger of widespread central nervous system (CNS) pathology. This intimate relationship between vision and neurodegeneration positions the eye as a functional and structural biomarker of MS. Yet, for too long, neurology and ophthalmology have operated in parallel rather than in concert.
- 29 September 2025
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 22 (2) , 1-2
Open AccessBridging Minds and Vision: The Need for Neurology and Ophthalmology Synergy in Multiple Sclerosis
Multiple sclerosis (MS) continues to challenge clinicians and researchers alike with its non-specific and heterogeneous presentation and unpredictable course. Among its earliest and most presenting features is visual dysfunction—commonly optic neuritis—which not only reflects localized optic nerve inflammation but also serves as a harbinger of widespread central nervous system (CNS) pathology. This intimate relationship between vision and neurodegeneration positions the eye as a functional and structural biomarker of MS. Yet, for too long, neurology and ophthalmology have operated in parallel rather than in concert.
- Open Access
- 31 December 2024
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 21 (4) , 18-24
Quality of Life in Individuals with Primary Headache Disorders: A Cross-Sectional Analysis at Tribhuvan University Teaching Hospital
Introduction: Headache disorders are among the most common health conditions worldwide, with a significant global burden, particularly from primary headaches such as migraine and tension-type headache (TTH). In Nepal, the prevalence of headache disorders is high, with a considerable portion of the population affected by these conditions. Primary headache disorders have been shown to negatively impact the quality of life (QoL) of individuals, both physically and mentally. Objective: This study aimed to assess the quality of life in patients diagnosed with primary headache disorders, including migraine, TTH, and other related conditions, at the Tribhuvan University Teaching Hospital in Nepal. Materials and methods: An observational descriptive cross-sectional study design was used, with a sample size of 211 patients diagnosed with primary headache disorders. Participants were selected using a non-probability convenience sampling method. A structured questionnaire was administered to collect demographic, clinical, and QoL-related data. The Quality of Life was measured using the Short Form (SF-36) questionnaire, which provides two key summary measures: the Physical Component Summary (PCS) and Mental Component Summary (MCS). Data was analyzed using SPSS Version 29, employing descriptive statistics, independent t-tests, ANOVA, and multiple linear regression to identify associations and predictors of QoL. Results: Preliminary results indicate that primary headache disorders significantly impair both the physical and mental health of affected individuals, as evidenced by lower PCS and MCS scores. Factors such as age, duration of illness, type of headache disorder, and medication use were identified as key determinants influencing the quality of life in these patients. Conclusion: The findings of this study highlight the substantial impact of primary headache disorders on the quality of life of individuals. Understanding the factors that contribute to the reduced QoL in these patients is crucial for developing effective interventions and improving the management of primary headache disorders in Nepal.
- 31 December 2024
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 21 (4) , 18-24
Open AccessQuality of Life in Individuals with Primary Headache Disorders: A Cross-Sectional Analysis at Tribhuvan University Teaching Hospital
Introduction: Headache disorders are among the most common health conditions worldwide, with a significant global burden, particularly from primary headaches such as migraine and tension-type headache (TTH). In Nepal, the prevalence of headache disorders is high, with a considerable portion of the population affected by these conditions. Primary headache disorders have been shown to negatively impact the quality of life (QoL) of individuals, both physically and mentally. Objective: This study aimed to assess the quality of life in patients diagnosed with primary headache disorders, including migraine, TTH, and other related conditions, at the Tribhuvan University Teaching Hospital in Nepal. Materials and methods: An observational descriptive cross-sectional study design was used, with a sample size of 211 patients diagnosed with primary headache disorders. Participants were selected using a non-probability convenience sampling method. A structured questionnaire was administered to collect demographic, clinical, and QoL-related data. The Quality of Life was measured using the Short Form (SF-36) questionnaire, which provides two key summary measures: the Physical Component Summary (PCS) and Mental Component Summary (MCS). Data was analyzed using SPSS Version 29, employing descriptive statistics, independent t-tests, ANOVA, and multiple linear regression to identify associations and predictors of QoL. Results: Preliminary results indicate that primary headache disorders significantly impair both the physical and mental health of affected individuals, as evidenced by lower PCS and MCS scores. Factors such as age, duration of illness, type of headache disorder, and medication use were identified as key determinants influencing the quality of life in these patients. Conclusion: The findings of this study highlight the substantial impact of primary headache disorders on the quality of life of individuals. Understanding the factors that contribute to the reduced QoL in these patients is crucial for developing effective interventions and improving the management of primary headache disorders in Nepal.
- Open Access
- 19 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1895-1900
SOFA and APACHE II scoring systems for predicting outcome of neurological patients admitted in a tertiary hospital intensive care unit
Background: The field of neurology encompasses the study and treatment of disorders that affect the nervous system, and patients with neurological conditions often require specialized care, particularly in the ICU. Predictive scoring systems are measures of disease severity used to predict patient outcomes. The aim of this study was to compare the discriminative power of commonly used scoring systems, namely the sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) in the ICU of a tertiary care hospital. Methods: This retrospective study included patients with neurological disorders in the ICUs of Tribhuvan University Teaching Hospital from 1 January 2022 to 31 December 2022. Results: A total of 153 patients were included. The mean age of the patients was 54.76 ± 17.32 years with higher male predominance (60.78%). Ischaemic stroke was the most common neurological disorder. There were 58 patients (37.9%) who required mechanical ventilation and all-cause mortality was 20.9%. The mean SOFA score was significantly higher (P=0.002) in survivors, whereas the mean APACHE II did not show a significant difference (P=0.238). Receiver operating characteristic (ROC) analysis showed the area of curve (AUC) of SOFA score was 0.765 and of APACHE II was 0.722. Conclusions: SOFA score had comparatively higher discriminative power than APACHE II. Assessment of the performance of scoring systems in a specific ICU setting improves the sensitivity and applicability of the model to these settings.
- 19 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (4) , 1895-1900
Open AccessSOFA and APACHE II scoring systems for predicting outcome of neurological patients admitted in a tertiary hospital intensive care unit
Background: The field of neurology encompasses the study and treatment of disorders that affect the nervous system, and patients with neurological conditions often require specialized care, particularly in the ICU. Predictive scoring systems are measures of disease severity used to predict patient outcomes. The aim of this study was to compare the discriminative power of commonly used scoring systems, namely the sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) in the ICU of a tertiary care hospital. Methods: This retrospective study included patients with neurological disorders in the ICUs of Tribhuvan University Teaching Hospital from 1 January 2022 to 31 December 2022. Results: A total of 153 patients were included. The mean age of the patients was 54.76 ± 17.32 years with higher male predominance (60.78%). Ischaemic stroke was the most common neurological disorder. There were 58 patients (37.9%) who required mechanical ventilation and all-cause mortality was 20.9%. The mean SOFA score was significantly higher (P=0.002) in survivors, whereas the mean APACHE II did not show a significant difference (P=0.238). Receiver operating characteristic (ROC) analysis showed the area of curve (AUC) of SOFA score was 0.765 and of APACHE II was 0.722. Conclusions: SOFA score had comparatively higher discriminative power than APACHE II. Assessment of the performance of scoring systems in a specific ICU setting improves the sensitivity and applicability of the model to these settings.
- Open Access
- 27 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2490-2495
Stroke patterns and outcomes during the second wave of COVID-19 pandemic: a cross-sectional study
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected the number of stroke activations, admission of patients with various types of strokes, the rate and timely administration of reperfusion therapy, and all types of time-based stroke-related quality assessment metrics. In this study, we describe the different types of strokes, different delays in seeking and completing treatment occurring during the second wave of the COVID-19 pandemic, and predictors of outcome at 3 months follow-up. Materials and methods: This is a single-centered prospective cross-sectional study carried out from May 2021 to November 2021, enrolling patients with stroke. Data collected were demographic characteristics, stroke types and their outcomes, and different types of prehospital delays. Results: A total of 64 participants were included in the study with a mean age of 60.25±15.31 years. Ischemic stroke was more common than hemorrhagic stroke. The median time of arrival to the emergency room of our center was 24 h. The most common cause of prehospital delay was found to be delays in arranging vehicles. The median duration of hospital stays [odds ratio (OR)=0.72, PP<0.05) were found to be a predictor of good outcomes at 3 months follow-up on binary logistic regression. Conclusion: The factors that cause the delayed transfer to the hospital and onset of treatment should be addressed. Patient counseling about the likely prognosis can be done after evaluating the probable outcome based on the NIHSS score and median duration of hospital stay. Nevertheless, mechanisms should be developed to reduce the prehospital delay at the ground level as well as at the policy level.
- 27 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2490-2495
Open AccessStroke patterns and outcomes during the second wave of COVID-19 pandemic: a cross-sectional study
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected the number of stroke activations, admission of patients with various types of strokes, the rate and timely administration of reperfusion therapy, and all types of time-based stroke-related quality assessment metrics. In this study, we describe the different types of strokes, different delays in seeking and completing treatment occurring during the second wave of the COVID-19 pandemic, and predictors of outcome at 3 months follow-up. Materials and methods: This is a single-centered prospective cross-sectional study carried out from May 2021 to November 2021, enrolling patients with stroke. Data collected were demographic characteristics, stroke types and their outcomes, and different types of prehospital delays. Results: A total of 64 participants were included in the study with a mean age of 60.25±15.31 years. Ischemic stroke was more common than hemorrhagic stroke. The median time of arrival to the emergency room of our center was 24 h. The most common cause of prehospital delay was found to be delays in arranging vehicles. The median duration of hospital stays [odds ratio (OR)=0.72, PP<0.05) were found to be a predictor of good outcomes at 3 months follow-up on binary logistic regression. Conclusion: The factors that cause the delayed transfer to the hospital and onset of treatment should be addressed. Patient counseling about the likely prognosis can be done after evaluating the probable outcome based on the NIHSS score and median duration of hospital stay. Nevertheless, mechanisms should be developed to reduce the prehospital delay at the ground level as well as at the policy level.
- Open Access
- 27 March 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (4) , 926-930
Wallerian degeneration in the brain after organophosphorus poisoning: a case report
Introduction and Importance: The type, quantity, and potency of the organophosphorus compound (OPC) taken determine the symptoms of OPC poisoning as well as their severity. The exact etiology for organophosphorus (OP) poisoning delay neuropathy regulating Wallerian degeneration is still unknown. Case Presentation: We report here a rare case of a 25-year-old lady with Wallerian degeneration in the brain found in an MRI in a patient after OPC ingestion. MRI of the brain, in our case, shows Wallerian degeneration of the corona radiata, internal capsule, and midbrain. Clinical Discussion: Some OPCs can lead to OP-induced delayed neuropathy, a form of delayed neurotoxicity in humans (OPIDN). The distal axonopathy’s (in OPIDN) morphological pattern resembles Wallerian degeneration, which happens in vitro following nerve damage. Although delayed Wallerian degeneration from organophosphate poisoning often affects the peripheral nervous system, it can also affect the central nervous system. Rehabilitation therapy combined with appropriate nursing care has been demonstrated to improve the disease. Conclusion: Central nervous system involvement after OP poisoning is rare, and MRI of the brain and spinal cord can document evidence of Wallerian degeneration after OP poisoning.
- 27 March 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (4) , 926-930
Open AccessWallerian degeneration in the brain after organophosphorus poisoning: a case report
Introduction and Importance: The type, quantity, and potency of the organophosphorus compound (OPC) taken determine the symptoms of OPC poisoning as well as their severity. The exact etiology for organophosphorus (OP) poisoning delay neuropathy regulating Wallerian degeneration is still unknown. Case Presentation: We report here a rare case of a 25-year-old lady with Wallerian degeneration in the brain found in an MRI in a patient after OPC ingestion. MRI of the brain, in our case, shows Wallerian degeneration of the corona radiata, internal capsule, and midbrain. Clinical Discussion: Some OPCs can lead to OP-induced delayed neuropathy, a form of delayed neurotoxicity in humans (OPIDN). The distal axonopathy’s (in OPIDN) morphological pattern resembles Wallerian degeneration, which happens in vitro following nerve damage. Although delayed Wallerian degeneration from organophosphate poisoning often affects the peripheral nervous system, it can also affect the central nervous system. Rehabilitation therapy combined with appropriate nursing care has been demonstrated to improve the disease. Conclusion: Central nervous system involvement after OP poisoning is rare, and MRI of the brain and spinal cord can document evidence of Wallerian degeneration after OP poisoning.
- Open Access
- 25 March 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (4) , 922-925
MRI of the brain mimicking autoimmune encephalitis in Sjögren syndrome with chorea: a case report
Introduction and importance: Neurologic manifestations in primary Sjögren syndrome (SS) range in prevalence from 8 to 49%, and most of the studies suggest a prevalence of 20%. The incidence of SS patients developing movement disorders is about 2%. Case presentation: The authors herein report a case of a 40-year-old lady with MRI of the brain mimicking autoimmune encephalitis in SS who presented with chorea. Her MRI findings revealed T2 and FLAIR (fluid-attenuated inversion recovery) high signal intensity areas in bilateral middle cerebellar peduncles, dorsal pons, dorsal midbrain, hypothalami, and medial temporal lobes. Clinical discussion: There is still no evidence to support the definite use of MRI in characterizing the central nervous system involvement in primary SS, especially due to overlapping findings with age and cerebrovascular disease. Multiple areas of increased signal intensity in periventricular and subcortical white matter in FLAIR and T2-weighted image is commonly seen in primary SS patients. Conclusion: It is crucial to consider autoimmune diseases like SS as a cause of chorea in adults, even in those whose imaging findings are suggestive of autoimmune encephalitis.
- 25 March 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (4) , 922-925
Open AccessMRI of the brain mimicking autoimmune encephalitis in Sjögren syndrome with chorea: a case report
Introduction and importance: Neurologic manifestations in primary Sjögren syndrome (SS) range in prevalence from 8 to 49%, and most of the studies suggest a prevalence of 20%. The incidence of SS patients developing movement disorders is about 2%. Case presentation: The authors herein report a case of a 40-year-old lady with MRI of the brain mimicking autoimmune encephalitis in SS who presented with chorea. Her MRI findings revealed T2 and FLAIR (fluid-attenuated inversion recovery) high signal intensity areas in bilateral middle cerebellar peduncles, dorsal pons, dorsal midbrain, hypothalami, and medial temporal lobes. Clinical discussion: There is still no evidence to support the definite use of MRI in characterizing the central nervous system involvement in primary SS, especially due to overlapping findings with age and cerebrovascular disease. Multiple areas of increased signal intensity in periventricular and subcortical white matter in FLAIR and T2-weighted image is commonly seen in primary SS patients. Conclusion: It is crucial to consider autoimmune diseases like SS as a cause of chorea in adults, even in those whose imaging findings are suggestive of autoimmune encephalitis.
- Open Access
- 1 September 2022
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 17 (03) , 407-411
Venture of a Tertiary Care Neurosurgical Center in Course of COVID-19 Lockdown without RT-PCR
“I will not permit considerations of age, disease or disability, creed, ethnic origin, gender, nationality, political affiliation, race, sexual orientation, social standing or any other factor to intervene between my duty and my patient.” Obliged by the aforementioned oath, no medical practitioner shall sit in a moral judgment on any patient but will treat their illness to the best of their ability whatever the circumstances. A clear concord was yet to be authorized after the World Health Organization (WHO) declared the global pandemic of severe acute respiratory syndrome coronavirus 2infection. As a diagnostic modality, WHO recommended real-time reverse transcription–polymerase chain reaction (RT-PCR) as a reliable test; however, its availability in a deprived nation like ours became a major restraining factor. Despite an asset of having high specificity, RT-PCR for coronavirus disease 2019has its own liability of having low sensitivity. Henceforth, as time passed by, the validity of the rapid diagnostic tests was put into question. In later months, a few centers around our periphery started conducting RT-PCR, but the time taken to obtain the result was long-drawn-out process and the patient who needed urgent neurosurgical intervention at Annapurna Neurological Institute and Allied Sciences had to wait. We would like to share our expedition through peaks and valleys of managing 215 patients during the vicious circle of lockdown and global pandemic. Article published online: 01 September 2022 © 2022. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 September 2022
- Published by Georg Thieme Verlag KG in Asian Journal of Neurosurgery
- Vol. 17 (03) , 407-411
Open AccessVenture of a Tertiary Care Neurosurgical Center in Course of COVID-19 Lockdown without RT-PCR
“I will not permit considerations of age, disease or disability, creed, ethnic origin, gender, nationality, political affiliation, race, sexual orientation, social standing or any other factor to intervene between my duty and my patient.” Obliged by the aforementioned oath, no medical practitioner shall sit in a moral judgment on any patient but will treat their illness to the best of their ability whatever the circumstances. A clear concord was yet to be authorized after the World Health Organization (WHO) declared the global pandemic of severe acute respiratory syndrome coronavirus 2infection. As a diagnostic modality, WHO recommended real-time reverse transcription–polymerase chain reaction (RT-PCR) as a reliable test; however, its availability in a deprived nation like ours became a major restraining factor. Despite an asset of having high specificity, RT-PCR for coronavirus disease 2019has its own liability of having low sensitivity. Henceforth, as time passed by, the validity of the rapid diagnostic tests was put into question. In later months, a few centers around our periphery started conducting RT-PCR, but the time taken to obtain the result was long-drawn-out process and the patient who needed urgent neurosurgical intervention at Annapurna Neurological Institute and Allied Sciences had to wait. We would like to share our expedition through peaks and valleys of managing 215 patients during the vicious circle of lockdown and global pandemic. Article published online: 01 September 2022 © 2022. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 8 February 2022
- Published by Annapurna Neurological Institute & Allied Sciences in Annapurna Journal of Health Sciences
- Vol. 2 (1) , 20-24
Azathioprine in the Treatment of Multiple Sclerosis: A Single Center Experience from Nepal
Introduction: Azathioprine is used as an off - label drug for the treatment of multiple sclerosis. It is one of the oldest and most widely used immunosuppressants that targets T and B lymphocytes and thus reduces the relapse and slows down the disease progression with the almost same efficacy as the other disease modifying drugs for multiple sclerosis. But due to its side effect profile it isn’t used as a standard choice of treatment. However, its cost effectiveness and oral route of administration makes it a drug of choice in a low socioeconomic country. This paper highlights the diagnosis of Multiple Sclerosis based on McDonald’s criteria and treatment with Azathioprine. Methods: It is a retrospective analysis was conducted among 32 patients suffering from Multiple sclerosis and treated with Azathioprine at tertiary neurological institue.Patients outcome was also documented reaching them individually. Results: Among 19 patients all were female with highest prevalence among age group of 30-39 years old. 60% had relapsing remitting Multiple sclerosis, 45% of the patients present with ocular symptoms followed by 31% patients with lower limb weakness and spasticity. 30% did not develop any relapse, 15.8% patients developed one episode of relapse, 21.1% patients relapsed twice while 21.1% patients relapsed thrice during the study period. 85% patients showed signs of improvements with Azathioprine therapy in terms of decreased neurological residual deficits and less complication. Conclusion: Azathioprine shows improvement, slows the rate of relapse with minimal evidence of side effects and no evidence of malignancy in patients with multiple sclerosis.
- 8 February 2022
- Published by Annapurna Neurological Institute & Allied Sciences in Annapurna Journal of Health Sciences
- Vol. 2 (1) , 20-24
Open AccessAzathioprine in the Treatment of Multiple Sclerosis: A Single Center Experience from Nepal
Introduction: Azathioprine is used as an off - label drug for the treatment of multiple sclerosis. It is one of the oldest and most widely used immunosuppressants that targets T and B lymphocytes and thus reduces the relapse and slows down the disease progression with the almost same efficacy as the other disease modifying drugs for multiple sclerosis. But due to its side effect profile it isn’t used as a standard choice of treatment. However, its cost effectiveness and oral route of administration makes it a drug of choice in a low socioeconomic country. This paper highlights the diagnosis of Multiple Sclerosis based on McDonald’s criteria and treatment with Azathioprine. Methods: It is a retrospective analysis was conducted among 32 patients suffering from Multiple sclerosis and treated with Azathioprine at tertiary neurological institue.Patients outcome was also documented reaching them individually. Results: Among 19 patients all were female with highest prevalence among age group of 30-39 years old. 60% had relapsing remitting Multiple sclerosis, 45% of the patients present with ocular symptoms followed by 31% patients with lower limb weakness and spasticity. 30% did not develop any relapse, 15.8% patients developed one episode of relapse, 21.1% patients relapsed twice while 21.1% patients relapsed thrice during the study period. 85% patients showed signs of improvements with Azathioprine therapy in terms of decreased neurological residual deficits and less complication. Conclusion: Azathioprine shows improvement, slows the rate of relapse with minimal evidence of side effects and no evidence of malignancy in patients with multiple sclerosis.
- Open Access
- 27 August 2021
- Published by Hindawi Limited in Case Reports in Neurological Medicine
- Vol. 2021, 1-3
Recurrent Bilateral Optic Neuritis Associated with Myelin Oligodendrocyte Glycoprotein Antibody: A Case Report from Nepal
Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated inflammatory condition involving spinal cord and optic nerves. Diagnosis of NMOSD is done by aquaporin-4 antibody (AQP4) in patients with optic neuritis. Myelin oligodendrocyte glycoprotein (MOG) expressed on the oligodendrocyte cell surface and on the outermost cell surface of the myelin sheath may also be present in patients with NMOSD bilateral optic neuritis. Here, we describe a case of a thirty-nine-year-old-female with recurrent bilateral optic neuritis with positive anti-MOG antibody, and anti-MOG syndrome has not previously been reported from Nepal.
- 27 August 2021
- Published by Hindawi Limited in Case Reports in Neurological Medicine
- Vol. 2021, 1-3
Open AccessRecurrent Bilateral Optic Neuritis Associated with Myelin Oligodendrocyte Glycoprotein Antibody: A Case Report from Nepal
Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated inflammatory condition involving spinal cord and optic nerves. Diagnosis of NMOSD is done by aquaporin-4 antibody (AQP4) in patients with optic neuritis. Myelin oligodendrocyte glycoprotein (MOG) expressed on the oligodendrocyte cell surface and on the outermost cell surface of the myelin sheath may also be present in patients with NMOSD bilateral optic neuritis. Here, we describe a case of a thirty-nine-year-old-female with recurrent bilateral optic neuritis with positive anti-MOG antibody, and anti-MOG syndrome has not previously been reported from Nepal.
- Open Access
- 8 August 2021
- Published by Annapurna Neurological Institute & Allied Sciences in Annapurna Journal of Health Sciences
- Vol. 1 (2) , 11-15
Challenges Faced for Botulinum Toxin Injection in the Treatment of Hemifacial Spasm and Blepharospasm: Our Experience in Tribhuvan University Teaching Hospital during COVID-19 Pandemic
Introduction: Hemi facial spasm (HFS) and Blepharospasm (BS) is a chronic distressing condition. Botulinum toxin (BoNT) injection is one of its treatment modality. Acquiring the injection and treating the patients overcoming the lockdown hurdles of COVID pandemic has been a major challenge. Methods: Patients who were treated at Tribhuvan University Teaching Hospital (TUTH) Outpatient Department (OPD) during the COVID pandemic in 2020 and 2021 were included in this study. Results: Out of 30 patients, 77% were female. 47% were diagnosed with BS whereas the rest with HFS. About 50% of them have had symptoms for an average of 2-5 years before receiving botulinum toxin injection. The mean Jankovic score for patients before BoNT was 2.31(SD: 0.66 range 1-4). 26 patients experienced a decrease in spasm within one week of BoNT injection and had symptomatic relief. The mean Jankovic score at week 1 was 0.63(SD: 1.09 range 1-3) and the difference was statistically significant (pConclusion: BoNT injection has a good outcome for HFS and BS, despite its cost and the need for frequent injection. Importing the BoNT from India during the lockdown period of COVID pandemic and patients travelling within the country were challenges that were faced by the patients and doctors to achieve the result.
- 8 August 2021
- Published by Annapurna Neurological Institute & Allied Sciences in Annapurna Journal of Health Sciences
- Vol. 1 (2) , 11-15
Open AccessChallenges Faced for Botulinum Toxin Injection in the Treatment of Hemifacial Spasm and Blepharospasm: Our Experience in Tribhuvan University Teaching Hospital during COVID-19 Pandemic
Introduction: Hemi facial spasm (HFS) and Blepharospasm (BS) is a chronic distressing condition. Botulinum toxin (BoNT) injection is one of its treatment modality. Acquiring the injection and treating the patients overcoming the lockdown hurdles of COVID pandemic has been a major challenge. Methods: Patients who were treated at Tribhuvan University Teaching Hospital (TUTH) Outpatient Department (OPD) during the COVID pandemic in 2020 and 2021 were included in this study. Results: Out of 30 patients, 77% were female. 47% were diagnosed with BS whereas the rest with HFS. About 50% of them have had symptoms for an average of 2-5 years before receiving botulinum toxin injection. The mean Jankovic score for patients before BoNT was 2.31(SD: 0.66 range 1-4). 26 patients experienced a decrease in spasm within one week of BoNT injection and had symptomatic relief. The mean Jankovic score at week 1 was 0.63(SD: 1.09 range 1-3) and the difference was statistically significant (pConclusion: BoNT injection has a good outcome for HFS and BS, despite its cost and the need for frequent injection. Importing the BoNT from India during the lockdown period of COVID pandemic and patients travelling within the country were challenges that were faced by the patients and doctors to achieve the result.